Key result
rhBNP improves acute hemodynamics and biomarkers in acute HF but fails to improve long-term mortality.
Why the study?
Optimizing treatment strategies for acute cardiovascular diseases is crucial for improving patient prognosis, while clinical evidence regarding the renal protection and long-term outcomes of recombinant human B-type natriuretic peptide (rhBNP) remains mixed.
This narrative review synthesizes the multi-target hemodynamic, cardioprotective, renoprotective, and anti-inflammatory mechanisms of recombinant human B-type natriuretic peptide (rhBNP) in acute heart failure and myocardial infarction, highlighting that while short-term surrogate improvements are well-documented, evidence for long-term clinical outcomes remains mixed.
Acute benefits may inform short-term management in HF and MI; leaves open optimal dosing for renal and prognostic effects.
Acute cardiovascular diseases have become a serious public health challenge worldwide. Optimizing treatment strategies is crucial for improving the prognosis of patients. Recombinant human B-type natriuretic peptide (rhBNP) has garnered significant attention due to its multi-target mechanisms of action. This article aims to comprehensively review the multi-target effects of rhBNP in the treatment of acute cardiovascular diseases, and briefly explain its molecular mechanism through the activation of natriuretic peptide receptors and multiple downstream signaling pathways. In addition, combined with the latest clinical evidence, the optimization strategies for the clinical application of rhBNP are deeply discussed. However, it is important to acknowledge that current clinical evidence regarding renal protection and long-term clinical outcomes remains mixed. This review aims to provide evidence-based, individualized treatment recommendations for clinical practice, thereby improving the clinical outcomes of patients with acute cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
周亚玲 et al. (2026) conducted a review in Acute heart failure and acute myocardial infarction. Recombinant human B-type natriuretic peptide (rhBNP / nesiritide) vs. Standard care, placebo, nitroglycerin, or monotherapy comparators was evaluated. Recombinant human B-type natriuretic peptide improves acute hemodynamics and cardiac biomarkers in acute heart failure and myocardial infarction, though long-term mortality outcomes remain neutral.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on HFrEF treatmentMore from Frontiers in Pharmacology